[1]汤路路,李明,徐燕.血清COX-2、Apelin、IGF-1与妊娠期甲状腺功能减退症患者母婴结局关系研究[J].陕西医学杂志,2025,54(8):1113-1117,1123.[doi:DOI:10.3969/j.issn.1000-7377.2025.08.021]
　TANG Lulu,LI Ming,XU Yan.Relationship between serum COX-2,Apelin,IGF-1 and maternal and fetal outcomes in patients with hypothyroidism during pregnancy[J].,2025,54(8):1113-1117,1123.[doi:DOI:10.3969/j.issn.1000-7377.2025.08.021]
点击复制

血清COX-2、Apelin、IGF-1与妊娠期甲状腺功能减退症患者母婴结局关系研究

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
54
期数:
2025年8期
页码:
1113-1117,1123
栏目:
临床检验
出版日期:
2025-08-05

文章信息/Info

Title:
Relationship between serum COX-2,Apelin,IGF-1 and maternal and fetal outcomes in patients with hypothyroidism during pregnancy
作者:
汤路路; 李明; 徐燕
（徐州医科大学附属淮安医院妇产科，江苏 淮安 223002）
Author(s):
TANG Lulu; LI Ming; XU Yan
(Department of Obstetrics and Gynecology,the Affiliated Huai’an Hospital of Xuzhou Medical University,Huai’an 223002,China)
关键词:
妊娠期甲状腺功能减退症; 环氧合酶-2; Apelin; 胰岛素样生长因子-1; 母婴结局
Keywords:
Hypothyroidism during pregnancy; COX-2; Apelin; IGF-1; Maternal and fetal outcomes
分类号:
R 714.256
DOI:
DOI:10.3969/j.issn.1000-7377.2025.08.021
文献标志码:
A
摘要:
目的：探讨妊娠期甲状腺功能减退症患者血清环氧合酶-2（COX-2）、Apelin、胰岛素样生长因子-1（IGF-1）水平变化及其与母婴结局的关系。方法：选取妊娠期甲状腺功能减退症患者320例为观察组。另选取同期产检健康孕妇320例为对照组。比较两组血清COX-2、Apelin、IGF-1水平，采用Pearson法分析血清COX-2、Apelin、IGF-1水平与患者甲状腺功能指标的相关性。记录并比较两组孕妇不良母婴结局发生情况，且根据母婴结局将观察组分为母婴结局不良组（111例）和母婴结局良好组（209例）。比较不同母婴结局患者临床资料，采用二元Logistic回归分析妊娠期甲状腺功能减退症患者发生母婴不良结局的影响因素。结果：观察组血清COX-2、Apelin水平高于对照组，IGF-1水平低于对照组（均P<0.05）。血清COX-2、Apelin与TSH水平呈正相关，与游离三碘甲状腺原氨酸（FT3）、游离甲状腺素（FT4）水平呈负相关（均P<0.05）。血清IGF-1与促甲状腺激素（TSH）水平呈负相关，与FT3、FT4水平呈正相关（均P<0.05）。观察组宫内发育迟缓、低出生体重儿及胎儿窘迫发生率高于对照组，且母婴不良结局总发生率高于对照组（均P<0.05）。母婴结局不良组患者有不良妊娠史、焦虑抑郁、甲状腺过氧化物酶抗体（TPOAb）阳性比例及血清COX-2、Apelin、TSH水平高于母婴良好组，血清IGF-1、FT4水平低于母婴结局良好组（均P<0.05）。不良妊娠史、焦虑抑郁、TPOAb阳性及血清COX-2、Apelin、IGF-1、FT4、TSH为妊娠期甲状腺功能减退症患者发生母婴不良结局的独立影响因素（均P<0.05）。结论：妊娠期甲状腺功能减退症患者血清COX-2、Apelin水平升高，IGF-1水平降低，三者与母婴结局有关，是患者发生母婴不良结局的影响因素。
Abstract:
Objective:To investigate the changes in serum cyclooxygenase-2 (COX-2),Apelin and insulin-like growth factor-1 (IGF-1) levels in patients with hypothyroidism during pregnancy and their relationship with maternal and fetal outcomes.Methods：A total of 320 patients with hypothyroidism during pregnancy were selected as the observation group.Another 320 healthy patients who had prenatal examinations during the same period were selected as the control group.The levels of serum COX-2,Apelin and IGF-1 were compared between the two groups.Pearson correlation analysis was used to analyze the correlation between serum COX-2,Apelin,IGF-1 levels and thyroid function indicators in patients.The occurrence of adverse maternal and fetal outcomes was recorded and compared between the two groups.The observation group was further divided into a poor maternal and fetal outcome group (111 cases) and a good maternal and fetal outcome group (209 cases) based on the outcomes.Clinical data of patients with different maternal and fetal outcomes were compared,and binary logistic regression analysis was used to identify the influencing factors of adverse maternal and fetal outcomes in patients with hypothyroidism during pregnancy.Results:The levels of serum COX-2 and Apelin were higher in the observation group than in the control group,while the level of IGF-1 was lower (all P<0.05).Serum COX-2 and Apelin levels were positively correlated with TSH levels and negatively correlated with FT3 and FT4 levels (all P<0.05).Serum IGF-1 levels were negatively correlated with TSH levels and positively correlated with FT3 and FT4 levels (all P<0.05).The incidence of intrauterine growth retardation,low birth weight infants,and fetal distress was higher in the observation group than in the control group,and the total incidence of adverse maternal and fetal outcomes was also higher (all P<0.05).Patients in the poor maternal and fetal outcome group had a higher proportion of adverse pregnancy history,anxiety and depression,TPOAb positivity,and higher levels of serum COX-2,Apelin and TSH,and lower levels of serum IGF-1 and FT4 than those in the good maternal and fetal outcome group (all P<0.05).Adverse pregnancy history,anxiety and depression,TPOAb positivity,and serum COX-2,Apelin,IGF-1,FT4 and TSH were identified as independent influencing factors for adverse maternal and fetal outcomes in patients with hypothyroidism during pregnancy (all P<0.05).Conclusion:Elevated levels of serum COX-2 and Apelin and decreased levels of IGF-1 in patients with hypothyroidism during pregnancy are related to adverse maternal and fetal outcomes and are influencing factors for such outcomes.

参考文献/References:

[1]刘春晓,范建霞.妊娠合并甲状腺功能减退的妊娠期监测和处理[J].实用妇产科杂志,2023,39(5):336-339.
[2]张培恒,孙伟杰,张杨,等.中枢性甲状腺功能减退症合并妊娠1例并文献复习[J].国际内分泌代谢杂志,2024,44(6):427-429.
[3]ALINIA T,HOVSEPIAN S,POUR H R,et al.The longitudinal growth trajectory of children with congenital hypothyroidism during the first 3 years of life[J].Eur J Pediatr,2024,183(9):4123-4131.
[4]张瑞倩.血清甲状腺激素成纤维细胞生长因子-21环氧化酶-2在妊娠合并亚临床甲状腺功能减退中的水平及相关性研究[J].中国妇幼保健,2024,39(1):18-22.
[5]任为为,王超,孟俊华,等.个体化预测甲状腺功能减退孕妇发生妊娠期糖尿病的风险预测Nomogram模型的建立与验证[J].实用临床医药杂志,2024,28(16):93-97.
[6]李仕康,曾浪,王坤,等.甲状腺功能障碍与心力衰竭的因果关系:两样本孟德尔随机化分析[J].实用心脑肺血管病杂志,2024,32(7):36-39.
[7]DAI C,CHEN C,JIANG L,et al.Severe neonatal hyperbilirubinemia secondary to combined RhC hemolytic disease,congenital hypothyroidism and large adrenal hematoma:A case report[J].BMC Pediatr,2022,22(1):539.
[8]宋圆华,刘霞,李祯,等.血清脂蛋白相关磷脂酶A2、新饱食分子蛋白-1水平对2型糖尿病患者并发亚临床甲状腺功能减退症的预测价值[J].陕西医学杂志,2022,51(12):1593-1596.
[9]李春雨,牟童,白明暄,等.《妊娠和产后甲状腺疾病诊治指南(第2版)》解读[J].实用妇产科杂志,2020,36(10):741-744.
[10]孙霞,杨宏杰,张曾,等.疏肝解毒法治疗桥本甲状腺炎甲状腺功能减退期临床研究[J].陕西中医,2023,44(12):1726-1729,1734.
[11]RAMOS M M,MAESTA I,DE ARAUJO COSTA R A,et al.Clinical characteristics and thyroid function in complete hydatidiform mole complicated by hyperthyroidism[J].Gynecol Oncol,2022,165(1):137-142.
[12]刘芝兰,黄燕.左甲状腺素治疗妊娠合并甲状腺功能低下在孕早期和孕中期的效果比较[J].广东医学,2024,45(4):505-509.
[13]欧阳钤,许雅娟,班彦杰,等.益生菌治疗孕中期妊娠期亚临床甲状腺功能减退合并小肠细菌过度生长的疗效研究[J].中国实用妇科与产科杂志,2023,39(5):562-567.
[14]彭茸,赖雪梅,任钧,等.妊娠合并甲状腺功能减退对自然流产的影响因素研究[J].中国妇产科临床杂志,2023,24(2):167-170.
[15]屈勇,李晶.孕早中晚期甲状腺功能减退孕妇血清甲状腺激素水平与低出生体重儿相关性研究[J].陕西医学杂志,2023,52(5):604-607.
[16]李淑英,葛晓春,刘锐,等.妊娠期糖尿病合并甲状腺功能减退症的危险因素及对妊娠结局的影响[J].河北医学,2022,28(10):1640-1644.
[17]何男,张宜生.左甲状腺素钠片治疗妊娠期甲状腺功能减退症的效果[J].江苏医药,2023,49(8):830-834.
[18]CUMMINGS N,LANTZ M,GOMEZABREU N,et al.Infusing the “motivation” into motivational interviewing:Addressing unique challenges in older adults with substance use disorders[J].Am J Geriat Psychiat,2023,31(3):s70-s71.
[19]吴秉司,梅海云,张晓立,等.老年2型糖尿病合并临床甲状腺功能减退及亚临床甲状腺功能减退患者血清apelin水平变化及意义[J].临床和实验医学杂志,2022,21(21):2296-2299.
[20]裴燕,王磊.孕早期亚临床甲减与妊娠并发症,妊娠结局及子代婴幼儿精神与运动发育的相关性[J].中国计划生育学杂志,2022,30(7):1591-1594.
[21]刘雪伟,李鲲鹏,宋君宇,等.Apelin和IRS-2蛋白与胃癌患者预后的关系[J].检验医学,2024,39(5):438-442.
[22]向静瑶,王晓瑜,徐开渝,等.生长激素缺乏症患儿血清IGF-1、Apelin、25(OH)D水平及与生长激素的相关性[J].解放军医药杂志,2022,34(7):71-74.
[23]刘娜,李迎歌.巴中地区重型β-TM患儿生长发育情况与HGB和SF水平的相关性[J].公共卫生与预防医学,2023,34(3):137-140.
[24]邵雪华,范海玲.亚临床甲状腺功能减退孕妇对子代神经免疫学指标神经心理及行为发育的影响[J].中国妇幼保健,2024,39(15):2845-2849.
[25]王丽萍,牛尚梅,柴巧英,等.甲状腺功能亢进症患者血清神经调节蛋白4水平及其临床意义[J].检验医学与临床,2024,21(14):2025-2029.

备注/Memo

备注/Memo:
江苏省卫生健康委员会科研计划项目（2021SF-1062）
更新日期/Last Update: 2025-08-04